Table 3.
Baseline Characteristics of Patients in the Propensity Score Matching Cohort
| Patients After PSM (n=66) | Sarcopenia (n=33) | Non-Sarcopenia (n=33) | P value | |
|---|---|---|---|---|
| Age (years) | 56.14±11.66 | 58.30±12.57 | 53.97±10.42 | 0.132 |
| L3 SMI (cm²/ m²) | 40.02±13.08 | 30.46±3.39 | 49.57±12.14 | <0.001 |
| BMI (kg/m²) | 24.68±3.42 | 24.73±4.00 | 24.62±2.77 | 0.900 |
| Tumor size (cm) | 4.00(3.00–6.00) | 4.00(2.90–6.00) | 5.00(3.00–5.05) | 0.781 |
| Tumor number | 1.00(1.00–1.00) | 1.00(1.00–1.00) | 1.00(1.00–1.00) | 1.000 |
| Total bilirubin (µmol/L) | 13.85(11.65–18.20) | 14.00(11.65–17.95) | 13.60(11.45–19.00) | 0.768 |
| GGT (IU/L) | 52.00(34.75–107.75) | 49.00(34.00–146.50) | 54.00(34.50–80.00) | 0.476 |
| ALT (IU/L) | 35.50(21.75–52.25) | 36.00(25.50–54.00) | 32.00(19.50–47.50) | 0.336 |
| AST (IU/L) | 33.00(23.75–49.75) | 36.00(25.00–55.50) | 27.00(21.50–45.50) | 0.084 |
| ALB (g/L) | 42.81±5.18 | 41.59±6.24 | 44.03±3.55 | 0.055 |
| HDL (mmol/L) | 1.14(0.97–1.32) | 1.14(0.96–1.29) | 1.14(0.98–1.52) | 0.478 |
| LDL (mmol/L) | 2.51(2.12–2.78) | 2.33(2.10–2.78) | 2.62(2.21–2.90) | 0.551 |
| TG (mmol/L) | 1.31(0.91–1.71) | 1.12(0.80–1.71) | 1.33(0.94–1.77) | 0.305 |
| AFP (ng/mL) | 7.49(3.58–289.40) | 10.45(3.87–390.00) | 5.21(2.76–201.93) | 0.307 |
| Gender, [n (%)] | 0.769 | |||
| Female | 15(22.7%) | 7(21.2%) | 8(24.2%) | |
| Male | 51(77.3%) | 26(78.8%) | 25(75.8%) | |
| BCLC stage | 0.800 | |||
| 0 | 41(62.1%) | 21(63.6%) | 20(60.6%) | |
| A | 25(37.9%) | 12(36.4%) | 13(39.4%) | |
| Child Pugh grade | 0.778 | |||
| A | 49(74.2%) | 25(75.8%) | 24(72.7%) | |
| B | 17(25.8%) | 8(24.2%) | 9(27.3%) | |
| Hypertension, [n (%)] | 0.602 | |||
| NO | 44(66.7%) | 23(69.7%) | 21(63.6%) | |
| YES | 22(33.3%) | 10(30.3%) | 12(36.4%) | |
| Diabetes, [n (%)] | 0.142 | |||
| NO | 51(77.3%) | 23(69.7%) | 28(84.8%) | |
| YES | 15(22.7%) | 10(30.3%) | 5(15.2%) | |
| Cirrhosis, [n (%)] | 0.447 | |||
| NO | 41(62.1%) | 22(66.7%) | 19(57.6%) | |
| YES | 25(37.9%) | 11(33.3%) | 14(42.4%) | |
| Ascites, [n (%)] | 0.314 | |||
| NO | 65(98.5%) | 32(97%) | 33(100.0%) | |
| YES | 1(1.5%) | 1(3%) | 0(0%) | |
| Satellite nodule, [n (%)] | 1.000 | |||
| NO | 60(90.9%) | 30(90.9%) | 30(90.9%) | |
| YES | 6(9.1%) | 3(9.1%) | 3(9.1%) | |
| Tumor thrombus, [n (%)] | 1.000 | |||
| NO | 64(97.0%) | 32(97.0%) | 32(97.0%) | |
| YES | 2(3.0%) | 1(3.0%) | 1(3.0%) | |
| Lymph node metastasis, [n (%)] | 0.314 | |||
| NO | 65(98.5%) | 32(97.0%) | 33(100.0%) | |
| YES | 1(1.5%) | 1(3.0%) | 0(0.0%) | |
| Extrahepatic metastasis, [n (%)] | 0.314 | |||
| NO | 65(98.5%) | 32(97.0%) | 33(100.00%) | |
| YES | 1(1.5%) | 1(3.0%) | 0(0.00%) | |
| HBV status, [n (%)] | 0.453 | |||
| Negative | 27(40.9%) | 15(45.5%) | 12(36.4%) | |
| Positive | 39(59.1%) | 18(54.5%) | 21(63.6%) | |
| HCV status, [n (%)] | 1.000 | |||
| Negative | 66(100.0%) | 33(100.0%) | 33(100.0%) | |
| Positive | 0(0.0%) | 0(0.0%) | 0(0.0%) | |
| MVI, [n (%)] | 1.000 | |||
| Negative | 56(84.8%) | 28(84.8%) | 28(84.8%) | |
| Positive | 10(15.2%) | 5(15.2%) | 5(15.2%) | |
| High differentiation, [n (%)] | 0.555 | |||
| NO | 63(95.5%) | 32(97.0%) | 31(93.9%) | |
| YES | 3(4.5%) | 1(3.0%) | 2(6.1%) |
Abbreviations: L3 SMI, L3 skeletal muscle index; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; MAFLD, metabolic dysfunction-associated fatty liver disease; BCLC, Barcelona clinic liver cancer; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ- glutamyl transpeptidase; TG, triglycerides; AFP, alpha-fetoprotein; HDL, High-density lipoprotein; LDL, low-density lipoprotein; MVI, microvascular invasion.